Atlas Private Wealth Advisors Has $745,000 Stake in Medtronic PLC $MDT

Atlas Private Wealth Advisors cut its position in shares of Medtronic PLC (NYSE:MDT) by 47.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,819 shares of the medical technology company’s stock after selling 7,164 shares during the quarter. Atlas Private Wealth Advisors’ holdings in Medtronic were worth $745,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MDT. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new stake in Medtronic in the third quarter worth approximately $29,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC bought a new position in shares of Medtronic during the 3rd quarter worth approximately $34,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.9%

NYSE:MDT opened at $102.96 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33. The company has a market cap of $131.99 billion, a PE ratio of 27.75, a PEG ratio of 2.66 and a beta of 0.71. The firm has a 50-day moving average of $99.60 and a 200-day moving average of $95.64.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.8%. Medtronic’s dividend payout ratio is 76.55%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of research reports. Robert W. Baird set a $103.00 target price on shares of Medtronic in a research report on Tuesday, December 16th. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Stifel Nicolaus upped their price objective on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. UBS Group increased their price objective on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Finally, Wells Fargo & Company began coverage on Medtronic in a research report on Friday. They issued an “overweight” rating and a $114.00 target price for the company. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).